GlassScriptPhysician profile
Wendy Barrett
NPI 1932554565
$4,800.39
in general payments reported to CMS, 2019-2025
32 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $125 · 2022: $498 · 2023: $1,155 · 2024: $1,733 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,891 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,891.21 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $862.80 | 2019-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $707.41 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $522.09 | 2022-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $404.26 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $303.81 | 2019-2025 | Spravato |
| Gilead Sciences, INC. | $242.46 | 2024-2025 | Descovy |
| Astellas Pharma US INC | $224.82 | 2023-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $199.99 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $181.52 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $168.41 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $119.77 | 2022 | |
| Edwards Lifesciences Corporation | $91.64 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $80.37 | 2022-2025 | |
| Hologic Sales and Service, LLC | $77.37 | 2023-2025 | Thinprep 2000 Processor, Aptima |
| Merck Sharp & Dohme LLC | $77.24 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $70.70 | 2023-2024 | Inogen |
| Sumitomo Pharma America, INC. | $63.60 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.93 | 2024-2025 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $47.91 | 2022-2023 | Quviviq |
| Abiomed | $44.84 | 2025 | |
| Viiv Healthcare Company | $39.25 | 2025 | Apretude |
| Otsuka America Pharmaceutical, INC. | $25.02 | 2025 | Rexulti |
| Dexcom, INC. | $23.50 | 2023 | Dexcom G6 Transmitter |
| Sebela Pharmaceuticals INC. | $21.56 | 2019 | |
| Hikma Pharmaceuticals USA | $21.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.85 | 2025 | Jardiance |
| Vertical Pharmaceuticals, LLC | $19.76 | 2025 | Relexxii |
| Esperion Therapeutics, INC. | $17.55 | 2025 | Nexletol |
| Amneal Pharmaceuticals LLC | $17.36 | 2024 | Unithroid |
| Aimmune Therapeutics, INC. | $15.62 | 2025 | Zenpep |
| Medtronic, INC. | $14.30 | 2025 | Minimed 780g |
| Chiesi USA, INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.